| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
NBD-557 targets the HIV-1 envelope glycoprotein gp120. It binds to the CD4-binding site on gp120, mimicking the interaction of the CD4 receptor. By binding to gp120, NBD-557 induces conformational changes that inhibit the interaction between gp120 and CD4, thereby blocking viral entry. This mechanism prevents HIV-1 from entering host cells. The compound is structurally related to NBD-556.
|
|---|---|
| ln Vitro |
In vitro, NBD-557 inhibits HIV-1 entry by blocking the interaction between gp120 and CD4. It shows activity against various HIV-1 strains. The compound's binding to gp120 and antiviral activity have been characterized in biochemical and cell-based assays. Detailed in vitro data are available in the primary literature. NBD-557 is a valuable tool for studying HIV-1 entry mechanisms.
|
| ln Vivo |
In vivo data for NBD-557 are limited in publicly available sources. Based on its in vitro anti-HIV-1 activity, the compound is expected to be useful for in vivo studies of HIV-1 infection. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile. The compound is a research tool for antiviral applications.
|
| Enzyme Assay |
In vitro HIV-1 entry inhibition assays for NBD-557 typically use HIV-1 pseudoviruses or replication-competent viruses and susceptible cell lines (e.g., TZM-bl cells). The compound is dissolved in DMSO and diluted in culture medium. Cells are pre-treated with NBD-557 at various concentrations (0.001-100 μM) for 30-60 minutes, followed by virus addition. Viral entry is assessed by measuring reporter gene expression (e.g., luciferase) or viral replication. IC₅₀ values are calculated from dose-response curves. Controls include vehicle and known entry inhibitors. Binding to gp120 is assessed by ELISA or surface plasmon resonance.
|
| Cell Assay |
For cell-based assays, susceptible cell lines (e.g., TZM-bl, Jurkat) are cultured in appropriate medium. Cells are seeded in multi-well plates and pre-treated with NBD-557 at various concentrations for 30-60 minutes. HIV-1 pseudoviruses or replication-competent viruses are added. Viral entry is assessed by measuring reporter gene expression or viral replication. Cell viability is assessed by MTT or CellTiter-Glo. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, NBD-557 may be administered to animals for antiviral efficacy studies. The compound is formulated in a suitable vehicle. For HIV-1 infection models, humanized mice or other susceptible models are infected and treated with NBD-557 at various regimens. Endpoints include viral load reduction, CD4 cell count, and survival. Blood samples are collected for pharmacokinetic analysis. All procedures follow institutional guidelines.
|
| ADME/Pharmacokinetics |
NBD-557 (MW 367.44, C₂₀H₂₅N₃O₄) is an HIV-1 entry inhibitor. The compound is soluble in DMSO. Detailed pharmacokinetic parameters are not extensively reported in publicly available sources. The compound is typically stored at -20°C. It is for research purposes. Further ADME studies are needed to fully characterize its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
NBD-557 is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions. Toxicity data are limited in publicly available sources.
|
| Additional Infomation |
NBD-557 is a research-grade CD4-mimetic HIV-1 entry inhibitor for studying viral entry mechanisms and antiviral drug discovery. Its primary applications include virology, HIV research, and drug discovery. The compound is not approved for clinical use. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves binding to gp120 and blocking CD4-gp120 interaction.
|
| Molecular Formula |
C17H24BRN3O2
|
|---|---|
| Molecular Weight |
382.302
|
| Exact Mass |
381.105
|
| CAS # |
333352-59-3
|
| PubChem CID |
5279270
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.182
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
441
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C(NC1CC(C)(NC(C)(C1)C)C)=O)NC2=CC=C(C=C2)Br
|
| InChi Key |
QQRFLGRIDNNARB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H24BrN3O2/c1-16(2)9-13(10-17(3,4)21-16)20-15(23)14(22)19-12-7-5-11(18)6-8-12/h5-8,13,21H,9-10H2,1-4H3,(H,19,22)(H,20,23)
|
| Chemical Name |
N'-(4-bromophenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide
|
| Synonyms |
NBD557; NBD 557; NBD-557
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~26.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6157 mL | 13.0787 mL | 26.1575 mL | |
| 5 mM | 0.5231 mL | 2.6157 mL | 5.2315 mL | |
| 10 mM | 0.2616 mL | 1.3079 mL | 2.6157 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
